Widely regarded as an innovative, successful biotech firm, Amgen led its industry in revenue and sales growth in 2007. This book reveals the highs and lows it experienced in the race to develop drugs. It takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its success.
Prenumerera på vårt nyhetsbrev för att få fantastiska erbjudanden och inspiration för din nästa läsning.
Genom att registrera dig accepterar du vår personuppgiftspolicy.